ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QLS2309

A development code.

Its studies are mostly in Hematologic Neoplasms, led by Qilu Pharmaceutical.

Furthest: phase 1, since Sep 5, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 1since Sep 5, 2025Sep 5, 2025Dec 2027phase 1 · NCT07173595

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2025First study: phase 1 study in RecurrenceFirst studyNCT07173595 · 186 planned · China

Ahead

  1. Dec 2027Primary completion: phase 1 study in RecurrenceNCT07173595

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07173595Recurrence · China1RecruitingDec 2027186

How it is read

Names in the registry

  • “QLS2309”, 1 entry

Codes read as this program: QLS2309.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.